The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global dry eye syndrome market was valued at US$ 4.5 Billion in 2022.
We expect the global dry eye syndrome market to exhibit a CAGR of 5.67% during 2023-2028.
Increasing prevalence of dry eye syndrome as a common symptom for numerous medical ailments, such as Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, etc., represents one of the key factors driving the global dry eye syndrome market.
Sudden outbreak of the COVID-19 pandemic had led to a severe decline in hospital or clinic visits for mitigating the risk of coronavirus infection, thereby negatively impacting the demand for dry eye syndrome diagnosis and treatment procedures.
Based on the disease type, the global dry eye syndrome market has been divided into evaporative dry eye syndrome and aqueous dry eye syndrome, where evaporative dry eye syndrome currently holds the majority of the total market share.
Based on the drug type, the global dry eye syndrome market can be segregated into lubricant eye drops, anti-inflammatory drugs, and autologous serum eye drops. Among these, anti-inflammatory drugs exhibit the clear dominance in the market.
Based on the product, the global dry eye syndrome market has been bifurcated into liquid drops, gel, liquid wipes, eye ointment, and others. Currently, liquid eye drops represent the majority of the total market share.
Based on the distribution channel, the global dry eye syndrome market can be categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Among these, hospital pharmacies currently account for the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global dry eye syndrome market include Akorn Inc., Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., and Santen Pharmaceutical Co. Ltd.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at